Welcome to BioMarket Group!

The Gastrointestinal Market Outlook to 2010

Additional Information

Published Date Feb 1, 2006
Special Offer No
Pages 156
PDF Fact Sheet View Fact Sheet for the report The Gastrointestinal Market Outlook to 2010 in PDF format.
Published on Date No
Format No
Publisher Business Insights
Product Line No
Full Title No

Availability: In stock

$2,875.00

Quick Overview

This report provides comprehensive coverage of the major GIT markets, incorporating a detailed epidemiological analysis of the major indications and key factors impacting their prevalence.
Request free sample pages from The Gastrointestinal Market Outlook to 2010

Executive Summary

This report provides comprehensive coverage of the major GIT markets, incorporating a detailed epidemiological analysis of the major indications and key factors impacting their prevalence; using IMS data, it provides analysis of current leading brands of treatment within each GIT indication provides an invaluable insight into the dynamics of the market, while profiling the pharmaceutical companies and relevant market trends that influence the sales of GIT treatments. This report further provides forecasts of major products over the 2005-10 period and the underlying trends affecting the future of the GIT market. By providing coverage of over 90% of the total market for GIT products and highlighting key players, this report allows the reader to gain a thorough understanding of the issues that are driving the transformation of the GIT market, and understand the likely direction that this market will take over the next 5 years.

Request free sample pages from The Gastrointestinal Market Outlook to 2010

Other selected research from the 'Gastroenterology' category:


Commercial and Pipeline Perspectives: Upper GI Disorders - Life Cycle Management Key as Generics and OTC Threaten Growth
The blockbuster PPI class in the US has been exposed to both generic and OTC competition. The impact of these events will shape the dynamics of the PPI market in the near and medium term, as the marketers of PPIs fight to maintain patent protection, prescription status, and formulary positioning. Meanwhile, a new generation of therapies is in development: a new class of fast acting APAs. Learn More


Commercial and Pipeline Perspectives: Lower GI Disorders - Remicade Leads Growth as Novel Biologics Compete for Market Share in Inflammatory Bowel Disease
IBD pipeline products are set to challenge Remicade and other existing therapies in the management of the disease. Competition will intensify as CDP870, Antegren, and Humira provide new alternatives in the severe Crohn`s disease market, and mode of administration will be a key element of product differentiation. In ulcerative colitis, drugs with novel mechanisms will compete for patient share. Learn More

Other selected research from the 'Markets' category:


Pharmaceuticals in Italy
Pharmaceuticals in Italy industry profile is an essential resource for top-level data and analysis covering the pharmaceuticals industry. Learn More


The World Contract Research and Manufacturing Market, 2006-2011: Trends in Outsourcing
The Contract Pharma market in 2005 was worth an estimated $57bn. Attitudes within the pharmaceutical industry are slowly changing and the use of strategic outsourcing is becoming an accepted practice. Learn More